Plavix vs brilique

Ticagrelor versus Clopidogrel in Patients with Acute

Plavix (clopidogrel bisulfate) is a thienopyridine class of drug that inhibits platelet aggregation and thus inhibits aspects of blood clotting used to treat patients with acute coronary syndrome, myocardial infarction (), peripheral vascular disease and some stroke (ischemic type) patients. Plavix is available in generic form Clopidogrel is an anti-platelet drug used for preventing strokes, heart attacks, and death in high-risk individuals who have had a heart attack, unstable angina, previous stroke, or have peripheral arterial disease (PAD).It prevents blood clots by binding to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP) from activating platelets Barbara - The recent studies looked at Plavix and aspirin for 12 months vs. 30 months. There really is no trial data measuring the effectiveness of this regimen for long periods such as yours (10 years). Just FYI, Plavix does not prevent the stent from tissue regrowth. It is meant to keep blood from clotting inside the stent New Guidance on Switching Between P2Y12 Inhibitors. A consensus document has been published, which gives clinicians the first set of viable guidelines to follow. According to the CDC's National Center for Health Statistics, cardiovascular disease remains the No. 1 cause of death in the United States. Contributing to this statistic is heart. Blockade of the P2Y 12-ADP receptor is critical in the care of acute coronary syndromes (ACS).Indeed, dual antiplatelet therapy (DAPT) is mandatory to prevent patients from ischemic recurrences (including stent thrombosis, myocardial infarction, and cardiovascular death) during these acute atherothrombotic events. 1 Clopidogrel remained the gold standard of P2Y 12-ADP receptor antagonists for.

Dual antiplatelet therapies with a P2Y 12 inhibitor and aspirin have shown to reduce ischemic events and stent thrombosis in patients with acute coronary syndromes (ACS) undergoing revascularization. 1 Clopidogrel (Plavix), a P2Y 12 inhibitor, in combination with aspirin was the standard of care in the management of ACS for several years until the development of newer agents This editorial refers to 'A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study' †, by F. Rollini et al. on page 2722. Clopidogrel is a thienopyridine prodrug, the active metabolite of which (CAM) inhibits the interaction of ADP with its platelet P2Y 12. *BRILINTA 180 mg initial dose given, followed by 90 mg twice daily. † Plavix 300 mg to 600 mg initial dose given, followed by 75 mg once daily Methods: We performed an observational analysis of all patients ≥80 years (n=14 005) who were discharged alive with aspirin combined with either clopidogrel (60.2%) or ticagrelor (39.8%) after a MI between 2010 and 2017 registered in the national registry SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended. ticagrelor over clopidogrel because of their superior net clinical benefits.1,2,4-6 Nev-ertheless, clopidogrel remains widely prescribed.7,8 The availability of different oral P2Y 12 inhibitors has enabled physicians to con-template switching among therapies because of specific clinical scenarios.9 The recent introduction of an intravenous P2Y 1

Brilinta Works Better Regardless of Genetic Makeup The findings come from a sub-study of the PLATO trial, which showed that Brilinta works better than Plavix at preventing heart attacks, strokes,.. Ticagrelor, a novel reversible inhibitor of the platelet adenosine diphosphate receptor P2Y12, was superior to clopidogrel, as add-on therapy to aspirin, in preventing stent thrombosis, cardiovascular outcome events, and death in patients undergoing coronary artery stenting, without causing an increase in major bleeding events treated with clopidogrel (2.4% vs 1.8%; P = 0.03). 2. However, most of the bleeding disparity was driven by 2 groups that . comprised 20% of the study population: patients with a his As compared to the clopidogrel group, the de-escalation group showed no significant differences in major bleeding (1.3% vs 3.6%, P = 0.23) or minor bleeding (7.9% vs 8.5%, P = 0.86) (Table 2). In the de-escalation group, the efficacy and safety outcomes were compared between the loading dose group and nonloading dose group (Table 3 )

Brilinta vs Plavix: what's the difference

Full data results of the PLATO health economics substudy demonstrate that even at a higher drug cost and incremental cost per acute coronary syndromes (ACS) patient, ticagrelor (Brilique, AstraZeneca) numerically lowered non-drug healthcare costs versus generic clopidogrel and is cost-effective.The results have been published online in the European Heart Journal BRILINTA 90 mg plus aspirin was studied vs clopidogrel plus aspirin in more than 18,000 patients, including STEMI (ST-elevation myocardial infarction), NSTEMI (non-ST-elevation myocardial infarction), and UA (unstable angina) patients, across 43 countries and 862 sites in the PLATO (PLATelet inhibition and patient Outcomes) study. 2 Patients were treated for at least 6 months and up to 12. The PEGASUS-TIMI 54 study investigated the efficacy and safety of both Brilique 60mg and 90mg, twice daily, compared to placebo on a background of low dose aspirin, for the long-term prevention of atherothrombotic events in patients who suffered a heart attack one to three years prior to enrolment

The guideline supports differentiation among currently available P2Y12 inhibitors, including Ticagrelor ( Brilinta; in Europe: Brilique ), Clopidogrel ( Plavix ), and Prasugrel ( Effient; in Europe: Efient ), for these patients Ticagrelor is known as BRILIQUE in the European Union and BRILINTA elsewhere and is indicated for the treatment of ACS. ACS continues to be a major cause of morbidity and loss of quality of life,(1) accounting for more than 40% of all CV deaths worldwide. non-CABG major bleeding was more common with ticagrelor versus clopidogrel (4.5% vs. As compared to the clopidogrel group, the de-escalation group showed no significant differences in major bleeding (1.3% vs 3.6%, P = 0.23) or minor bleeding (7.9% vs 8.5%, P = 0.86) (Table 2). In the de-escalation group, the efficacy and safety outcomes were compared between the loading dose group and nonloading dose group (Table 3 )

Clopidogrel is safer than ticagrelor in regard to bleeds

Blood samples will be collected at baseline (prior to clopidogrel dose), 12, 24, 48, 54, 60 and 72 hours post initiation of therapy. The primary endpoint is the difference in platelet inhibition between our 2 different groups (bolus vs no bolus), as measured by P2Y12 reaction unit (PRU) using the VerifyNow assay y. Therefore, some institutions and providers switch patients from ticagrelor or prasugrel to clopidogrel in an effort to lower bleeding risk, stem costs, or otherwise ensure that patients can safely adhere to long-term P2Y12 inhibitor therapy. From a pharmacodynamic perspective, switching patients from ticagrelor or prasugrel to clopidogrel comes at a cost of less antiplatelet efficacy. As alternative for Plavix, often Prasugrel (Efient, Effient) or Ticagrelor (Brilique) is used after stenting to avoid in stent thrombosis. I tried all three :-), all have their specific side effects. Problem could be the switching as you do not want to stop one medicin too long before starting another (risk of thrombosis) and also not overlap. Eliquis vs. Plavix: side effect and effectiveness comparison - a phase IV clinical study. Summary: We compare the side effects and drug effectiveness of Eliquis and Plavix. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 284,988 people who take Eliquis and Plavix, and is updated regularly In the 2018 consensus statement, experts say physicians can stop antiplatelet therapy with clopidogrel 12 months after PCI in nearly all patients. If the patient is at high risk of bleeding, antiplatelet therapy can be stopped at 6 months. by Michael O'Riordan. Michael O'Riordan is the Associate Managing Editor for TCTMD and a Senior Journalist

Plavix vs. Brilinta Treatment for Heart Disease ..

March 19, 2018. ORLANDO, FL—Patients with coronary artery disease who need to switch from ticagrelor to clopidogrel after PCI should receive a loading dose of 600 mg clopidogrel between 12 and 24 hours following ticagrelor discontinuation, according to results from a randomized, pharmacodynamic study. Findings from the SWAP-4 study should. Patients who get drug-eluting stents to open a blocked artery can stop taking aspirin after just three months, instead of the typical full year, and lower their risk of bleeding, a new study suggests Plavix (clopidogrel) is a brand-name prescription drug that's used to help prevent cardiovascular events. Learn about side effects, warnings, dosage, and more Brilique was compared with clopidogrel (another inhibitor of platelet aggregation) in a main study involving over 18,000 adults who had had a heart attack or had unstable angina. The patients also took aspirin and were treated for up to a year. The main measure of effectiveness was based on the number of patients having another heart attack, a. 1. Introduction. Antiplatelet agents (APAs) are prescribed to prevent arterial thrombosis and especially the recurrence of thrombotic events. The four main oral APAs have two distinct pharmacological targets: aspirin inhibits the enzyme cyclooxygenase 1 and therefore thromboxane A 2 synthesis, while clopidogrel, prasugrel and ticagrelor inhibit the adenosine diphosphate (ADP) pathway via the.

complications between the clopidogrel-prasugrel LD group and prasugrel only LD group. All-cause and cardiac mortality were similar between the groups, but in-hospital major adverse cardiac events were greater in the clopidogrel-prasugrel LD group (5.6% vs 1.6%, p=0.031), mainly driven by a greater rate of urgent CABG I had a heart attack and stent placed one year ago. I have been treated with Brilinta for the stent for one year. I just had a treadmill test which looked good, so my doctor told me to stop the Brilinta. She said standard protocol is to stop after a year. Being nervous about stopping, I asked her if she felt it was truly safe to stop

The Rapid Activity of Platelet Inhibitor Drugs Study showed that four hours is needed to achieve effective platelet inhibition in most patients, with just 50% of treated patients having effective. between the groups, ticagrelor compared to clopidogrel had more episodes of fatal intracranial bleeding (0.1% vs.0.01%, p=0.02). Note there were fewer episodes of other types of fatal bleeding in the ticagrelor group compared to the clopidogrel (0.1% vs. 0.3%, p=0.03).Ticagrelor had an increased incidence of dyspnoea compared to clopidogre

Plavix vs. Eliquis - RxLis

  1. The composite of death, MI or stroke at 12 months was higher with ticagrelor compared with prasugrel (9.3% vs 6.9%; HR 1.36; 95% confidence interval [CI] 1.09-1.70; p=0.006). The difference in the effects of the two treatments on the primary endpoint was primarily driven by rates of MI, which were 4.8% with ticagrelor and 3.0% with prasugrel.
  2. istration of ticagrelor (Brilinta/Brilique, AstraZeneca) was noninferior to clopidogrel in terms of major bleeding risk at 30 days in patients.
  3. Background: In patients presenting to the ED with acute coronary syndrome (ACS), dual antiplatelet therapy is the current standard treatment. This typically consists of aspirin and an adenosine diphosphate receptor antagonist. It is fairly well understood that prasugrel and ticagrelor provide greater, and more rapid platelet inhibition than clopidogrel (i.e. Plavix) [5][6]
  4. Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
  5. Ticagrelor (Brilique™ [EU]; Brilinta® [USA]), an oral antiplatelet agent, is indicated in combination with aspirin for the prevention of atherothrombotic events in adults with acute coronary syndromes (ACS). In a key 12-month trial in patients with ACS, ticagrelor plus aspirin prevented ischaemic events more effectively than clopidogrel plus aspirin, without increasing the risk of most.

The blinded review categorised differences in causes of post-bypass grafting deaths between treatment arms, and found that total rates of vascular deaths and non-vascular deaths from the time of bypass grafting until study end for the ticagrelor and clopidogrel groups were 4% (25/632) vs. 7.5% (47/629) and 0.6% (4/632) vs. 1.7% (11/629), respectively Tratamentul anticoagulant are ca tinta fluidizarea sangelui in interiorul arterelor. Persoanele cu o stare de sanatate buna nu sunt pasibile de a forma cheaguri decat atunci cand sufera o hemoragie, iar sangele se coaguleaza in afara arterelor Ticagrelor vs. clopidogrel en pacientes con SCA: PLATO Study Wallentin L et al. New Engl J Med 2009;361:1045-57 Days after randomisation 0 60 120 180 240 300 360 12 11 10 9 8 7 6 5 4 3 2 1 0 13 ) 9.8 Clopidogrel 11.7 Ticagrelor p=0.0003 HR 0.84 (95% CI 0.77-0.92) RRR = 16%, ARR = 1.87%, NNT = 54 N=18.624. Lek Plavix sadrži laktozu, monohidrat. Pacijenti sa retkim naslednim oboljenjem intolerancije na galaktozu, nedostatkom laktaze ili glukozno-galaktoznom malapsorpcijom ne smeju da uzimaju ovaj lek. Ovaj lek sadrži ricinusovo ulje, hidrogenizovano koje može izazvati stomačne tegobe i dijareju

anticoagulant warfarin, and antiplatelet agents aspirin and clopidogrel, have been widely used for many years and most dental practitioners will be familiar with well-established guidelines for the dental care of patients taking these drugs. However, in recent years several newer oral anticoagulant Plavix, marketed by Sanofi-Aventis and Bristol Myers-Squibb, is the world's second-best selling drug with annual revenue topping $9bn. If approved, Brilinta would compete directly with Plavix for. The marketing authorisation for BRILIQUE is based on a review of the ticagrelor clinical programme, including results from PLATO (A Study of PLATelet Inhibition and Patient Outcomes), which established the superiority of ticagrelor over clopidogrel, and showed that treating 54 ACS patients with ticagrelor instead of clopidogrel for one year. BRILINTA is a prescription medicine for adults used to: decrease your risk of death, heart attack, and stroke in people with a blockage of blood flow to the heart (acute coronary syndrome or ACS) or a history of a heart attack. BRILINTA can also decrease your risk of blood clots in your stent in people who have received stents for the treatment.

This information is intended for use by health professionals. 1. Name of the medicinal product. Brilique 90 mg orodispersible tablets. 2. Qualitative and quantitative composition. Each orodispersible tablet contains 90 mg ticagrelor. Brilique contains less than 1 mmol sodium (23 mg) per dose, i.e. is essentially 'sodium-free' There are several things you should avoid while taking Brilinta (ticagrelor), to minimize your risk of side effects from the medication. Brilinta is a blood thinner prescribed to prevent blood clots from forming and blocking blood vessels, which lowers your risk of heart attack or stroke

Plavix (clopidogrel) vs

If the patient is diagnosed myocardial infarction within one year before CABG, s/he continues lifelong aspirin, but clopidogrel or ticagrelor (brilique) is given one year from the day s/he had. Ticagrelor is an antiplatelet medicine, or blood thinner. It makes your blood flow through your veins more easily. This means your blood will be less likely to make a dangerous blood clot. Taking ticagrelor can help prevent blood clots if you have an increased risk of having them Im Vergleich zum VKA Warfarin war die Rate an Todesfällen und Klinikeinweisungen unter Apixaban signifikant um 17% niedriger (23,5% vs. 27,4%; HR 0.83; p = 0,002). Ausschlaggebend dafür war eine niedrigere Hospitalisierungsrate unter Apixaban (22,5% vs. 25,3%)

Plavix and Aspirin After Stent: 8 Years Later - Is Longer

Plavix VerifyNow test results are in P2Y12 reaction units (PRU). This test measures the extent of platelet aggregation in the presence of P2Y12 inhibitor drugs such as clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta) and ticlopidine (Ticlid). Aspirin VerifyNow test results are in aspirin resistance units (ARU) The most common adverse reactions associated with the use of BRILINTA included bleeding and dyspnea: In PLATO, for BRILINTA vs clopidogrel, non-CABG PLATO-defined major bleeding (3.9% vs 3.3%) and. In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogrel and ticagrelor 180 mg loading dose will be compared in acute coronary syndrome (ACS) patients undergoing PCI.. Clinical Trials Registry. ICH GCP Plavix, sold by Sanofi For this study, the price of generic Plavix at 17 euro cents per day was compared with a price range of Brilique at 2.25-3.50 euros per day, Astra said

Purpose: To verify whether the presence of atrial fibrillation (AF) impacts the platelet reactivity, particularly the efficacy of ADP receptor antagonists, and to verify whether there is a correlation between CHA2DS2VASc score and the efficacy of ADP receptor antagonists in the group of patients with AF after stent-PCI. Methods: The analysis of PCI registry was performed Brilique 90 mg film coated tablets. 1. Name of the medicinal product. 2. Qualitative and quantitative composition. Each film-coated tablet contains 90 mg ticagrelor. Brilique contains less than 1 mmol sodium (23 mg) per dose, i.e. is essentially 'sodium-free'. For the full list of excipients, see section 6.1

AstraZeneca is studying lower dose ticagrelor (60 mg bid vs. the usual 90 mg bid) for the prevention of atherothrombotic events in a massive Ph-III prevention trial in patients with stable vascular disease. This is the same population as was studied in the CHARISMA (clopidogrel) trial, and that Merck is studying in TRA 2˚P-TIMI 50 L'étude clinique « Clopidogrel or Ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT » a évalué les performances respectives du Clopidrogel (Plavix) et du Brilique (Ticagrelor) sur 2 062 patients atteints d'ACS (Acute coronary syndrome) dans le monde réel, traités par intervention coronarienne percutanée (PCI) avec des. Ticagrelor (Brilique, AZD6140, ARC126532)- is an oral, reversible, selective antagonist of the platelet 12 purinoP2Y receptor. It inhibits both platelet activation and aggregation in a reversible manner and was developed for the treatment of acute coronary syndromes (ACS) via the reduction of major cardiovascular and thromboembolic events O Ticagrelor (Brilique) keine LD, 2x90mg/d 600mg Plavix geloaded! Dokumentenname Datum Seite 33 Akutes Koronarsyndrom Nachbetreuung Entlassung. Dokumentenname Datum Seite 34 Frau B. 60j., 160cm/50kg Klinik: Intermittierende Thoraxschmerzen seit 2 Wochen, zuletzt gestern Nacht PA:-Labor

New Guidance on Switching Between P2Y12 Inhibitor

The study demonstrated that treatment with BRILIQUE led to a greater reduction in the primary end point - a composite of CV death, MI, or stroke - compared to patients who received clopidogrel [9. Plavix. Pradaxa. Marevan. Xarelto. Når du tar blodfortynnende midler, er det veldig viktig å følge legens anvisninger. Hopper du over, eller glemmer medisinen et par dager, øker risikoen for komplikasjoner, som hjerneslag og hjerteinfarkt, raskt. Tar du derimot for mange, kan det gi deg alvorlige blødninger The study demonstrated that treatment with BRILIQUE led to a greater reduction in the primary end point - a composite of CV death, MI, or stroke - compared to patients who received clopidogrel [9.8% vs. 11.7% at 12 months, 1.9% absolute risk reduction (ARR), 16% relative risk reduction (RRR), 95% CI, 0.77 to 0.92, p<0.001]

EUCLID: Ticagrelor, Clopidogrel in PAD Similar for CV Events

Ticagrelor Is the Best Antiplatelet Agent for Pretreatment

  1. Brilique 60 mg and 90 mg film coated tablets. tablet. Brilique 60 mg film-coated tablets. ticagrelor 90 mg twice daily showed superiority to 75 mg daily. Micardis vs avapro. Micardis official prescribing information for healthcare professionals. medicine plavix 75 mg tablet bri; trental ordering cheap online;
  2. Common Key Generics (Brands) Warfarin (Coumadin, Jantoven) Heparin and Low Molecular Weight Heparin (LMWH) MOA: Binds to antithrombin and indirectly deactivates coagulation factors by enhancing the effect of antithrombin. Side Effects: Increased risk of major bleeding - intracranial hemorrhage and GI bleeding
  3. Thereafter, Plavix or clopidogrel was favored over Ticlid because of better tolerance and decreased risk of neutropenia. Multi center trials clearly demonstrated the benefit of using dual anti-platelet (DAPT) consisting of aspirin and Plavix as superior to Coumadin or aspirin alone.. We currently follow a patient who underwent coronary stenting of the circumflex coronary artery in the early.
  4. So ticagrelor is an alternative to clopidogrel. It's what I'm on (with aspirin) and the only side effect I have is an increased tendency to bruise which shows it's working. You could ask to be tried on ticagrelor (also called Brilique or Brilinta

Comparison of Clopidogrel and Prasugrel for Prevention of

  1. Ticagrelor is known as BRILIQUE in the European Union and BRILINTA elsewhere. (CABG)-related major bleeding was more common with ticagrelor compared to clopidogrel (4.5% vs. 3.8%; p=0.03.
  2. or stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function allele and patients with large artery atherosclerosis. Design Open label, blinded endpoint.
  3. Title: Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Tria
  4. istered ADP analogue which changes the conformation of the platelet adenosine P2Y 12 receptor inhibiting the binding of ADP without the need for metabolic activation. Unlike clopidogrel and prasugrel, this inhibition is reversible

Switching from clopidogrel to prasugrel or ticagrelor

  1. Purpose: The purpose of this study is to investigate the potential acute and chronic effect of ticagrelor versus clopidogrel on arterial stiffness and other vascular risk markers of interest, the study will consist of two periods: a 24-hour ACUTE period where 60 subjects with an indication for coronary angiography (CA) with or without percutaneous coronary intervention (PCI) will be included.
  2. Ticagrelor (BRILINTA/BRILIQUE) is an investigational oral antiplatelet treatment for ACS. Ticagrelor is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo.
  3. -K-Antagonist plus dualer Plättchenhemmung erfolgen. Die PIONEER AF-PCI-Studie zeigt nun zwei Alternativen mit geringeren Blutungsrisiken auf

BRILINTA 90 mg vs Plavix BRILINTA® (ticagrelor) tablet

Still, the risk of these bleeding events was consistently lower with clopidogrel combined with 110-mg dabigatran vs triple therapy (14.5% vs 25.8%) or 150-mg dabigatran vs triple therapy (19.7% vs. Brilique [brilik] je moderní lék ze skupiny léků na ředění krve, odborněji řečeno jde o protisrážlivý lék ovlivňující krevní destičky. Jeho )činnou složkou je sloučenina tikagrelor.. Princip: Tikagrelor účinkuje na některé receptory krevních destiček (trombocytů) a narušuje jejich srážení.Je zde jistá podobnost se sloučeninou clopidogrel (např. léky. Clinical effectiveness . 3.1 For the comparison of ticagrelor plus aspirin with clopidogrel plus aspirin, the manufacturer identified one trial, the PLATO trial, an international, multicentre, randomised, double-blind, double-dummy, parallel group, phase III study. The trial evaluated the efficacy and safety of ticagrelor plus aspirin compared with clopidogrel plus aspirin over 12 months in. The price of generic clopidogrel €0.17 per day was compared with the price range of BRILIQUE of €2.25 to €3.50 per day and applied in the analysis to form the price component of the health economics substudy. Using individual patient data from PLATO and event rates, health care costs based on Swedish base-case analysis and QALYs were.

Clopidogrel; Brilique (ticagrelor) Efient (prasugrel) Læs mere om hver enkelt produkt længere nede. Blodprop i venerne. Vener er de blodårer, der fører blodet tilbage til hjertet. Blodpropper, der opstår i venerne, skyldes primært manglende cirkulation eller øget størkneberedskab i kroppen, og skyldes altså ikke åreforsnævring Ticagrelor is known as BRILIQUE in the European Union and BRILINTA elsewhere. For primary percutaneous coronary intervention (PCI), the guidelines now recommend ticagrelor with no restrictions for. 2008 Fukuuchi16 Clopidogrel vs. Ticlopidine 100% 12M IS 1151 573 578 73% 65 68% 19% 2008 PRoFESS, Sacco17 A_D vs. Clopidogrel 32% 30M IS 20332 10181 10151 64% 66 74% 29% 2008 S-ACCESS, Shinohara18 Sarpogrelate vs. Aspirin 100% 19M IS 1510 752 758 72% 65 70% 28% 2009 Guo19 Cilostazol vs. Aspirin 100% 12M IS 68 34 34 35% 60 NC N The price of generic clopidogrel €0.17 ($0.23) per day was compared with the price range of BRILIQUE of €2.25 ($3.00) to €3.50 ($4.65) per day and applied in the analysis to form the price component of the health economics substudy